News Archive

The content below is specific to Novartis Canada. To see all Novartis content, please visit the Novartis Global site.

2018

May

Media Release / May 02, 2018

Health Canada approves KISQALI(TM) for the treatment of HR-positive and HER2-negative metastatic breast cancer in postmenopausal women in combination with letrozole as an initial endocrine-based therapy

Read More

February

Media Release / Feb 12, 2018

Novartis launches new awareness campaign for metastatic breast cancer community

Read More
2017

December

Media Release / Dec 05, 2017

Health Canada approves Rydapt(TM) (midostaurin), first targeted therapy for common form of acute myeloid leukemia (AML)

Read More

November

Media Release / Nov 30, 2017

Phase III STRIVE study data for erenumab (AMG334) in migraine prevention published in The New England Journal of Medicine

Read More

October

Media Release / Oct 30, 2017

Novartis releases results of first controlled, randomized clinical trial specifically designed for pediatric multiple sclerosis (MS)

Read More

September

Media Release / Sep 26, 2017

Ride for Life: Novartis employees embark on a 600-km bike ride for breast cancer

Read More
Media Release / Sep 13, 2017

Cosentyx® demonstrates sustained results in psoriasis with 5-year Phase III data

Read More

June

Media Release / Jun 22, 2017

Psoriasis bodypainting campaign puts dermatologists ‘in their patients’ shoes’

Read More
Media Release / Jun 22, 2017

Top 10 Novartis Facts and Figures

Read More
Media Release / Jun 20, 2017

PrXolair® added to seven Canadian public drug plans to treat chronic idiopathic urticaria (hives)

Read More

Pages